Rome, Nov 4. (Adnkronos Health) – Givinostat, a molecule that “has been shown in clinical studies to slow down the progression of Duchenne muscular dystrophy” thanks to a new mechanism of action, wins the Prix Galien Italy in the ‘Rare Diseases’ category. The drug – a note informs – represents a story of Italian scientific excellence and is the result of Italfarmaco’s research and development. The award ceremony took place yesterday in Turin.
“The victory of the Prix Galien rewards not only an innovative molecule like givinostat, but also an entrepreneurial and scientific history built over time through constant investments in research and development – explains Francesco Di Marco, Group CEO –. The recognition takes on even greater significance because it comes in an area characterized by relevant medical needs and a strong need for innovation, where for a long time the available therapeutic options have been limited. This result enhances the innovation path undertaken by Italfarmaco and the ability of Italian research to generate scientific progress and translate it into concrete therapeutic solutions for patients.”
“This prestigious recognition fills us with pride – states Julie De Santis, member of the Board of Directors of Italfarmaco Holding –. Italfarmaco was founded in Milan in 1938. Strong in our family tradition, we are guided by a long-term vision, deeply rooted in our heritage and supported by an international team. In these 88 years, the company has constantly invested in research and development, and givinostat is the result of this commitment. We want to share the Prix Galien with the clinicians and patient associations who have made a decisive contribution to the development of the molecule. Our goal is to provide answers to unmet clinical needs, particularly in rare diseases, and thanks to givinostat, an important step forward has been made.”